DDP4i and SGLT2i combination will address ____pathophysiological defects leading to high blood glucose levels in T2DM patients (referring to ominous octet)

True or False:

Combination of Vildagliptin and Dapagliflozin complements reduction in HbA1c

Vildagliptin and Dapagliflozin offers complimentary body weight reduction in diabetic patients by ___ (vilda/dapa)

True or False:

DPP-4 inhibitors moderate (reduces) the risk of genitourinary tract infections associated with SGLT2 inhibitors.

Combination of Vildagliptin & Dapagliflozin complements reduction in ___. (More than 1 click possible)

According to DECLARE TIMI, Dapagliflozin shows reduction in hHF/CVD By____

According to which trial Dapagliflozin shows 39% reduction in Renal Composite Endpoint

DPP4i + SGLT2i Offers Complementary Benefits in Reducing Body Weight & ___